Arzerra Disappoints In NHL, Putting Genmab On Shaky Ground

Genmab and partner GlaxoSmithKline reported August 17 disappointing top-line results from a Phase II study of their anti-CD 20 antibody Arzerra in rituximab-refractory follicular non-Hodgkin's lymphoma, calling into question the biotech's future as an independent entity